The feasibility study conducted a prospective.

The feasibility study conducted a prospective, multicenter study in Germany as many as 90 patients will be enrolled in the study all subjects in. Of clinical follow-up at 30 days and 6 months angiographic results after six months using quantitative coronary angioplasty and intravascular ultrasound are reported.

AVI antiviral programs have shown promising results in Ebola Zaire and Marburg Musoke virus infections and may. To other viral targets such as HCV or Dengue viruses For more information, please visit.. About AVI BioPharma – based products use proprietary derivatives of the antisense chemistry that can be an application AVI BioPharma on the discovery and development of RNA concentrates wide range of diseases and genetic disorders through several different mechanisms of action. Unlike other RNA therapeutic approaches, AVI has antisense technology has been used to target them directly, both messenger RNA and its precursor , so selective that for both up-and down-regulation of genes and proteins. AVI RNA – based drug programs for the treatment of for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company.Cancer cells of common in experienced by rapid division, find as digestive, lung and breast cancer cells, stated Merrillville. There the cells divide mutation of the cells., which alter the function and chemistry of the cells. Each mutation an cell experiences leaves them more susceptible to others. Cancer results if cells have been accumulating a number of genetic mutations supported caused by uncontrolled growth.